Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reteplase - Angde Biotech Pharmaceutical

Next Previous
Drug Profile

Reteplase - Angde Biotech Pharmaceutical

Alternative Names: r-PA; Recombinant human tissue plasminogen kinase derivative - Angde Biotech Pharmaceutical; Recombinant human tissue plasminogen kinase derivative for injection - Angde Biotech Pharmaceutical; Recombinant plasminogen activator; Recombinant plasminogen kinase derivative - Angde Biotech Pharmaceutical; Ruitongli

Latest Information Update: 28 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Angde Biotech Pharmaceutical
  • Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
  • Mechanism of Action Plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ischaemic stroke
  • No development reported Pulmonary embolism

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for preclinical development in Pulmonary-embolism in China (IV, Injection)
  • 22 Jun 2023 Angde Biotech Pharmaceutical in collaboration with Beijing Tiantan Hospital completes a phase III trial in Stroke in China (IV) (NCT05295173)
  • 25 Mar 2022 Angde Biotech Pharmaceutical plans a phase III trial for Acute ischemic stroke (In adults, In the elderly) in China in March 2022 (IV) (NCT05295173)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top